Drug intelligence / Profile preview

eicosapentaenoic acid + alpha-lipoic acid

Development stage: Unknown
Administration: Oral, Intravenous

Overview

A combination of eicosapentaenoic acid (EPA), an omega-3 fatty acid found in cold-water fish, and alpha-lipoic acid (ALA), a naturally occurring antioxidant. This combination has been studied for weight management, reducing inflammation, and improving cardiovascular health markers. EPA contributes anti-inflammatory properties and helps maintain leptin levels during weight loss, while ALA provides antioxidant effects and may directly promote weight loss. Clinical studies suggest this combination may be particularly effective for overweight or obese individuals following energy-restricted diets.

Other names: eicosapentaenoic acid and alpha-lipoic acidEPA + ALAEPA + α-lipoic acid

Targets

LEPR (Leptin receptor)OADHCs (Mitochondrial 2-oxoacid dehydrogenase complexes)LEP (Leptin)

Beyond the preview

Go deeper on eicosapentaenoic acid + alpha-lipoic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eicosapentaenoic acid + alpha-lipoic acid.